| 丁婷婷,芮晓艳,范洪峰,张艳喜,陈 军,徐 锐.阿帕替尼联合多西他赛对多线治疗晚期非小细胞肺癌患者血清肿瘤标志物、免疫功能及生活质量的影响[J].,2021,(6):1160-1164 |
| 阿帕替尼联合多西他赛对多线治疗晚期非小细胞肺癌患者血清肿瘤标志物、免疫功能及生活质量的影响 |
| Effect of Apatinib Combined with Docetaxel on Serum Tumor Markers, Immune Function and Quality of Life in Patients with Multiline Therapy for Advanced Non-small Cell Lung Cancer |
| 投稿时间：2020-08-14 修订日期：2020-09-10 |
| DOI：10.13241/j.cnki.pmb.2021.06.036 |
| 中文关键词: 晚期非小细胞肺癌 阿帕替尼 多西他赛 多线治疗 肿瘤标志物 免疫功能 生活质量 |
| 英文关键词: Advanced non-small cell lung cancer Apatinib Docetaxel Multiline therapy Tumor markers Immune function Quality of life |
| 基金项目:国家自然科学基金项目(81303418)；安徽省卫生和计划生育委员会科研计划项目（2016QK012） |
|
| 摘要点击次数: 616 |
| 全文下载次数: 535 |
| 中文摘要: |
| 摘要 目的：分析阿帕替尼联合多西他赛用于多线治疗晚期非小细胞肺癌患者的临床效果。方法：选择我院2017年1月到2019年8月共86例晚期非小细胞肺癌患者为研究对象，按照随机抽签法分为对照组、观察组各43例，地塞米松预处理后，对照组仅应用多西他赛治疗，观察组联合应用阿帕替尼与多西他赛治疗，3周为1个治疗周期，均治疗4个周期。比较两组治疗前、治疗4周期后血清肿瘤标志物水平、免疫功能及生活质量及不良反应发生情况。结果：观察组治疗4周期后总缓解率为44.19%（19/43），高于对照组总缓解率23.26%（10/43）（P＜0.05）；治疗4周期后两组患者细胞角蛋白19片段抗原21-1（CYFRA21-1）、癌胚抗原（CEA）、糖蛋白抗原125(CA125)、鳞状上皮细胞癌抗原(SCC)水平、CD8+、生命质量测定量表EORTC QLQ-C30(QLQ-C30)中的功能及症状总得分均较治疗前降低，且观察组低于对照组（P＜0.05）；CD3+、CD4+、CD4+/CD8+水平及QLQ-C30的总体健康状况及生活质量总得分均高于治疗前，且观察组高于对照组（P＜0.05），两组患者治疗期间的不良反应发生率无差异（P＞0.05）。结论：阿帕替尼联合多西他赛用于多线治疗晚期非小细胞肺癌患者，可在一定程度上提高缓解率，其改善血清肿瘤标志物水平的效果更优，有助于提高患者机体免疫功能和生活质量，且短期内不会增加不良反应。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the effect of apatinib combined with docetaxel in the treatment of patients with advanced non-small cell lung cancer. Methods: From January 2017 to August 2019, a total of 86 patients with advanced non-small cell lung cancer who were treated in our hospital were selected as the research object, according to the random draw method, they were divided into control group and observation group, 43 cases in each group. After pretreatment with dexamethasone, the control group was used only application docetaxel treatment, observation group was used apatinib combined with docetaxel treatment. 3 weeks were a treatent cycle, all of which were 4 cycles. The serum tumor markers levels, immune function and quality of life and adverse reactions of two groups before treatment and 4 cycles after treatment were compared. Results: The total remission rate of the observation group at 4 cycles after treatment was 44.19%(19/43), which was higher than 23.26% (10/43)of the control group (P＜0.05). The levels of cytokerantin-19-fragment antigen21-1 (CYFRA21-1), carcinoembryonic antigen (CEA), glycoprotein antigen 125 (CA125) and squamous cell carcinoma antigen (SCC), CD8+, quality of life measurement scale EORTC QLQ-C30(QLQ-C30) function and symptoms total scores of the two groups at 4 cycles after treatment were lower than those before treatment, and those of observation group were lower than those of control group (P＜0.05). The levels of CD3+, CD4+ and CD4+/CD8+ and QLQ-C30 general health and quality of life total scores were higher than those before treatment, and those of the observation group were higher than those of the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion: Apatinib combined with docetaxel for the multiline treatment of patients with advanced non-small cell lung cancer can improve the remission rate to a certain extent, improve the level of serum tumor markers, help improve the immune function and quality of life of patients, and will not increase adverse reactions in the short term. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
